BEAT HeartBeam, Inc.
Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1779372 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY12.5%
TTM EPS YoY40.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-521.7%
ROA-335.9%
ROIC (approx.)—
Asset turnover—
Leverage & solvency
Liabilities / assets17.3%
Debt / equity0.00x
Current ratio4.64x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.69x
Accruals ratio-104.3%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | — | — | — | — | — |
| R&D expense | $13.45M | $11.05M | $6.80M | $5.68M | $255,000 |
| SG&A expense | $7.69M | $8.84M | $8.52M | $7.35M | $2.03M |
| Operating income | -$21.14M | -$19.89M | -$15.31M | -$13.03M | -$2.29M |
| Interest expense | — | — | — | — | $2.17M |
| Pretax income | -$21.02M | -$19.45M | -$14.64M | -$12.96M | -$4.43M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$21.02M | -$19.45M | -$14.64M | -$12.96M | -$4.43M |
| EBITDA | -$21.10M | -$19.88M | -$15.31M | — | — |
| EPS (basic) | -0.62 | -0.73 | -0.72 | -1.59 | -1.03 |
| EPS (diluted) | -0.62 | -0.73 | -0.72 | -1.59 | -1.03 |
| Weighted avg. shares (diluted) | 33.71M | 26.65M | 20.33M | 8.17M | 4.28M |
| Balance sheet | |||||
| Cash & equivalents | $4.38M | $2.43M | $16.24M | $3.59M | $13.19M |
| Inventory | $103,000 | $0 | — | — | — |
| Current assets | $4.68M | $2.77M | $16.82M | $4.04M | — |
| PP&E, net | $1.10M | $450,000 | $256,000 | $0 | — |
| Total assets | $5.84M | $3.28M | $17.13M | $4.04M | $14.00M |
| Current liabilities | $3.24M | $1.62M | $1.19M | — | — |
| Total liabilities | $3.24M | $1.62M | $1.19M | $1.67M | $588,000 |
| Shareholders' equity | $2.60M | $1.65M | $15.94M | $2.37M | $13.41M |
| Shares outstanding | 40.12M | 26.96M | 26.33M | 8.01M | 7.81M |
| Cash flow statement | |||||
| Operating cash flow | -$13.99M | -$14.47M | -$12.09M | -$9.95M | -$3.23M |
| Capital expenditure | $600,000 | $201,000 | $256,000 | $0 | — |
| Free cash flow | -$14.59M | -$14.67M | -$12.35M | -$9.95M | — |
| Investing cash flow | -$600,000 | -$201,000 | -$256,000 | $0 | — |
| Financing cash flow | $16.59M | $866,000 | $24.99M | $350,000 | $16.40M |
| Depreciation & amortization | $40,000 | $7,000 | $0 | — | — |
| Stock-based compensation | $5.15M | $4.30M | $3.21M | $1.12M | $192,000 |
Free plan shows the latest 5 periods; Pro shows all 6 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.